BIO-TECHNE Corp Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
BIO-TECHNE Corp (TECH) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $0 for the 12-month period ending 2014-06-30, per its 10-K filed 2014-08-29.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2014-08-29
- BIO-TECHNE Corp effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for the quarter ending 2012-06-30 was -$6.02M.
- BIO-TECHNE Corp effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for the quarter ending 2012-03-31 was $3.00M.
- BIO-TECHNE Corp effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2014 was $0.00.
- BIO-TECHNE Corp effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2013 was $0.00.
- BIO-TECHNE Corp effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2012 was -$3.02M, a 5126.67% decline from fiscal 2011.
- BIO-TECHNE Corp effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2011 was $60.00K, a 36.36% increase from fiscal 2010.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 3 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 6 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 9 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month |
|---|---|---|---|---|
| 2014-06-30 | $0.00 10-K · filed 2014-08-29 | |||
| 2013-06-30 | $0.00 10-K · filed 2014-08-29 | |||
| 2012-06-30 | -$6.02M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-29 | -$3.02M derived: sum of 2 quarters · filed 2014-08-29 | -$3.02M 10-K · filed 2014-08-29 | |
| 2012-03-31 | $3.00M 10-Q · filed 2013-05-10 | $3.00M 10-Q · filed 2013-05-10 | ||
| 2011-06-30 | $60.00K 10-K · filed 2013-08-29 | |||
| 2010-06-30 | $44.00K 10-K · filed 2012-08-29 | |||
| 2009-06-30 | -$235.00K 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |